跳转至内容
Merck
CN
  • In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.

In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba.

Antimicrobial agents and chemotherapy (2008-01-24)
Maria-Teresa Illnait-Zaragozi, Gerardo F Martínez, Ilse Curfs-Breuker, Carlos M Fernández, Teun Boekhout, Jacques F Meis
摘要

Cuban Cryptococcus isolates (n = 165) were tested in vitro against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole, giving MIC90 values of 0.25, 8, 4, 0.25, 0.125, 0.016, and 0.016 microg/ml, respectively. Isavuconazole and posaconazole seem to be potentially active drugs for treating cryptococcal infections.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
5-氟胞嘧啶, nucleoside analog